Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal ...
UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM ESTCompany ParticipantsAndrew Dickinson - Chief ...
Zacks Investment Research on MSN
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Gilead Sciences, Inc.’s GILD posted 3% year-over-year growth in total revenues for the third quarter of 2025. Total revenues comprise product sales and royalty, contract and other revenues. While ...
Some lawmakers and advocates are increasingly uncertain whether critical HIV and AIDS services will survive the federal government’s funding fight. The GOP’s House-passed budget bill seeks to cut over ...
Gilead Sciences, Inc. GILD posted better-than-expected third-quarter 2025 results and lifted the lower end of its product sales. Adjusted earnings per share (EPS) of $2.47 beat the Zacks Consensus ...
The U.S. drug maker reported revenues of $7.77 billion, beating the consensus of $7.45 billion. Product sales decreased 2% to $7.3 billion, primarily driven by lower Veklury (remdesivir) and Cell ...
Key goals of EHE include, from 2017 to the end of 2025, reducing new HIV infections and diagnoses by 75%, increasing viral suppression among PWH to 95%, and increasing good or better self-rated health ...
B/F/TAF shows lower ART switching rates and higher persistence among HIV patients, especially those with mental health or substance use disorders. Medicare claims data analysis indicates B/F/TAF has ...
In recent years, the story around HIV has shifted dramatically. What was once viewed as a life sentence is now increasingly seen as a manageable condition. Medication is responsible for much of that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback